Ensign Peak Advisors
SPRY icon

Ensign Peak Advisors’s ARS Pharmaceuticals SPRY Stock Holding History

Ensign Peak Advisors’s Portfolio SPRY Stock Details SPRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-346,024
Closed -$1.22M – 2201
2022
Q1 		$1.22M Sell
346,024
-63,951
-16% -$278K ﹤0.01% 1093
2021
Q4 		$2.73M Buy
+409,975
New +$3.33M 0.01% 850
2021
Q3 		– Sell
-5,000
Closed -$154K – 1880
2021
Q2 		$154K Hold
5,000
– – ﹤0.01% 1747
2021
Q1 		$218K Hold
5,000
– – ﹤0.01% 1722
2020
Q4 		$232K Buy
+5,000
New +$167K ﹤0.01% 1705

Other funds holding SPRY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
KPF
K2 Principal Fund Toronto, Ontario, Canada $1.43B AUM 29.56% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Ensign Peak Advisors's SPRY Position: Q2 2022 in Review

Ensign Peak Advisors sold out of ARS Pharmaceuticals (SPRY) in Q2 2022, closing a stake of 346,024 shares — an estimated $1.22M sold.

Ensign Peak Advisors first reported a position in SPRY in Q4 2020 and held it in 5 quarters. The position peaked at $2.73M in Q4 2021. 64 funds tracked by Wall St. Rank hold SPRY as of Q2 2022.

  • Ensign Peak Advisors reported no remaining ARS Pharmaceuticals position as of Q2 2022 after selling out during the quarter.
  • Ensign Peak Advisors sold 346,024 ARS Pharmaceuticals shares in Q2 2022, an estimated $1.22M.
  • Ensign Peak Advisors first reported a position in ARS Pharmaceuticals in Q4 2020 and held it in 5 quarters.
  • Ensign Peak Advisors's ARS Pharmaceuticals position peaked at $2.73M in Q4 2021.
  • 64 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q2 2022.

Based on Ensign Peak Advisors's 13F filing for Q2 2022, filed 12 Aug 2022.